CDK12 and prostate carcinoma: Knowing the prevalence of CDK12 alterations among various solid tumor types may be helpful for selectively evaluating for these mutations for prognostic and treatment purposes, particularly in the case of prostate cancer where biallelic CDK12 inactivation is associated with shorter time to biochemical progression and distant metastases.10